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Abstract
Background: Deposition of chromatin-IgG complexes within glomerular membranes is a key event in the pathogenesis of
lupus nephritis. We recently reported an acquired loss of renal Dnase1 expression linked to transformation from mild to
severe membranoproliferative lupus nephritis in (NZBxNZW)F1 mice. As this may represent a basic mechanism in the
progression of lupus nephritis, several aspects of Dnase1 expression in lupus nephritis were analyzed.
Methodology/Principal Findings: Total nuclease activity and Dnase1 expression and activity was evaluated using in situ
and in vitro analyses of kidneys and sera from (NZBxNZW)F1 mice of different ages, and from age-matched healthy controls.
Immunofluorescence staining for Dnase1 was performed on kidney biopsies from (NZBxNZW)F1 mice as well as from
human SLE patients and controls. Reduced serum Dnase1 activity was observed in both mesangial and end-stage lupus
nephritis. A selective reduction in renal Dnase1 activity was seen in mice with massive deposition of chromatin-containing
immune complexes in glomerular capillary walls. Mice with mild mesangial nephritis showed normal renal Dnase1 activity.
Similar differences were seen when comparing human kidneys with severe and mild lupus nephritis. Dnase1 was diffusely
expressed within the kidney in normal and mildly affected kidneys, whereas upon progression towards end-stage renal
disease, Dnase1 was down-regulated in all renal compartments. This demonstrates that the changes associated with
development of severe nephritis in the murine model are also relevant to human lupus nephritis.
Conclusions/Significance: Reduction in renal Dnase1 expression and activity is limited to mice and SLE patients with signs
of membranoproliferative nephritis, and may be a critical event in the development of severe forms of lupus nephritis.
Reduced Dnase1 activity reflects loss in the expression of the protein and not inhibition of enzyme activity.
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Introduction
Systemic lupus erythematosus (SLE) is a systemic autoimmune
disease characterized by the development of autoreactivity against
nuclear antigens, including double-stranded DNA (dsDNA) and
histones [1,2,3]. The predominance of chromatin-associated
antigen targets points at aberrancies in the processing and
elimination of chromatin as a potential culprit of such a process
[4,5,6,7,8]. It has been postulated that effective degradation of
DNA from dying cells is essential to prevent priming of the
immune system against chromatin self-antigens, and impaired
chromatin degradation has been proposed as a mechanism for the
development of antinuclear autoimmunity [9,10].
DNA fragmentation by the activation of various nucleases is
considered a key event in apoptotic cell death (reviewed in [11,12]).
For elimination of DNA from necrotic cells, secreted nucleases,
including Dnase1 are assumed to play a central role in this process
(reviewed in [11,13]). Under circumstances of increased cellular
stress, such as active infections, malignancies and tissue trauma,
increased amounts of DNA can be observed within the circulation,
suggesting that the capacity for DNA elimination is exceeded
[14,15,16]. Increased levels of circulating DNA and nucleosomes
have been reported in SLE [17,18,19], especially in active stages of
the disease [20] and in lupus-prone mice [21].
Dnase1 is considered the major serum nuclease, and has been a
topic of interest in the context of SLE for several decades. Dnase1
is the founding member of the Dnase1-like (Dnase1l) family of
divalent cation-dependent endonucleases, which also include
Dnase1l1-3. Reduced serum Dnase1 activity is a common finding
in SLE patients [22,23,24] and lupus-prone mice [25]. The basis
for increased concentration of DNA in the circulation remains
controversial [13], but possible explanations include ineffective
elimination of chromatin due to impaired nuclease activity, either
by decreased nuclease availability [23] or inhibition by factors
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therapy in mice and SLE patients have been largely disappointing
[28,29], as has experimental over-expression of Dnase1 in T-cells
in lupus-prone mice [30]. In contrast, experimental deletion of
Dnase1 in mice resulted in development of lupus-like disease,
including anti-chromatin autoantibody production and immune-
complex mediated glomerulonephritis [31]. Later studies revealed
that these effects were largely eliminated upon backcrossing into
one of the parental strains, suggesting that other predisposing
genetic aberrancies are required for the development of auto-
reactivity in this model. The data, however, suggest that elimi-
nating Dnase1 contributes to the acceleration of renal disease in
lupus-prone mice [13].
Taken together, these data suggest that Dnase1 deficiency alone
is not sufficient to induce autoimmunity against chromatin, but
may play a key role in progression of lupus nephritis. Whereas the
activity of Dnase1 in serum has been extensively studied
[22,23,25,33], little is known about its expression and activity
within different organs. In a recent study, we demonstrated that
the appearance of anti-dsDNA antibodies in (NZBxNZW)F1 (B/
W) mice coincided with early signs of development of mesangial
nephritis, while reduced renal Dnase1 mRNA expression corre-
lated with progression of lupus nephritis into end-stage organ
disease [32]. This recent data is indicative of loss of DNase1
serving as a possible factor in the progression of lupus nephritis.
The present study was designed to further characterize these
changes in terms of i. localization of renal Dnases in different
compartments of the kidneys, ii. their relative contribution to total
renal nuclease activity and iii. the relation between renal and
serum Dnase1 activity with initiation and progression of lupus
nephritis. Furthermore, to evaluate whether changes in Dnase1
expression could also be involved in the progression of the human
variant of lupus nephritis, renal Dnase1 expression was also
assayed in biopsies from SLE patients and correlated with
morphological and immune electron microscopy findings.
Results
Characteristics of the experimental animals
High anti-dsDNA antibody titer was present in all the animals
with nephritis irrespective of age (26–38 w.o.) and was elevated for
an average of 2 months prior to the development of overt
proteinuria [34]. Young B/W mice and BALB/c control mice of
all age groups had no clinical or laboratory signs of kidney disease.
Pre-proteinuric animals on average had only marginally elevated
anti-dsDNA antibody titers. The predominant pattern of glomer-
ular immune complex (IC) deposits was characterized by immune
electron microscopy (representative images are presented in Figure
S1). Based on these results, the proteinuric mice were divided into
two groups, one with mesangial IC deposits (Figure S1A–B), and
one with IC deposits in the glomerular capillary walls (Figure
S1C–D). The pre-nephritic mice had no glomerular deposits
(Figure S1E–F). Data presented below demonstrate the relevance
of these groups in identifying pathogenic factors in lupus nephritis.
Gene expression data for major apoptotic nucleases in the
kidneys from mice of different ages is presented in Table 1. The
results are expressed as fold change relative to 4 weeks old BALB/
c control mice and show that of all the renal nucleases studied,
only the mRNA level of Dnase1 was significantly reduced in the
group of mice with membranoproliferative nephritis. Lack of
down-regulation of other genes, including house-keeping genes or
genes encoding other renal nucleases, makes it unlikely that
reduced Dnase1 expression was due to renal insufficiency or loss of
viable renal cells (see below).
Total renal and serum nuclease activity in progressive
murine lupus nephritis
In order to evaluate the Ca
2+- and Mg
2+-dependent DNase
activity in kidneys and sera, kidney homogenates and sera from
individual B/W and BALB/c mice of different ages were analyzed
by single radial enzyme diffusion (SRED) assay. This allows
evaluation of net DNA degrading activity, taking into account the
effects of any Dnase1 inhibitory factors present within the samples.
There was a significant reduction in total nuclease activity in the
proteinuric B/W kidneys compared to those of both younger B/W
and age-matched BALB/c mice (Figure 1A). Importantly, the loss
of nuclease activity was only observed in mice with glomerular
capillary membrane deposits of chromatin fragment-IgG com-
plexes (p,0.001), while nuclease activity was normal in kidneys
with deposits confined to the mesangium (Figure 1A). Corre-
sponding assays for total serum nuclease activity revealed a less
pronounced but consistent decrease in the proteinuric mice
regardless of the pattern of glomerular chromatin-IgG deposits
(Figure 1A, p,0.001). No evidence of decreased serum nuclease
activity was seen in pre-nephritic mice or in B/W mice prior to
anti-dsDNA antibody production. Dnase1 differs from other
members of the Dnase1-like family of nucleases by its sensitivity
to inhibition by monomeric actin. Pre-incubating the gel in buffer
Table 1. Gene expression of apoptotic nucleases in kidneys
from (NZBxNZW)F1 and BALB/c mice from different age
groups.
Taqman assay Mouse Age
4 w.o. 8 w.o. 20 w.o. .26 w.o.
dnase1
Mm01342389_g1
B/W 1.1560.09
a 1.8260.18 1.6960.42 0.45±0.59
f
BALB/c 1.0760.42 1.5960.27 1.3060.49 1.4960.30
dnase2
Mm00438463_m1
B/W 0.8260.10 0.8160.18 1.3860.11 1.4360.19
BALB/c 1.0160.18 1.1960.23 1.0060.05 1.1660.22
endoG
b
Mm00468248_m1
B/W 0.8860.15 0.7860.19 1.0060.11 0.7660.23
BALB/c 1.0060.06 1.1860.20 1.0460.17 0.9860.03
Dffa
c
Mm00438410_m1
B/W 1.0960.14 0.8160.12 0.9460.08 1.2460.14
BALB/c 1.0060.09 1.1460.24 0.9860.16 0.8660.08
Dffb
d
Mm00432822_m1
B/W 0.8460.10 0.7460.13 0.8960.09 0.8760.13
BALB/c 1.0060.09 0.7860.16 0.8160.03 0.6860.20
Cideb
e
Mm00438213_m1
g
B/W 1.2260.23 1.0460.15 1.4860.33 1.0960.52
BALB/c 1.0160.11 1.2860.22 1.0060.17 1.1660.15
aThe data are presented as fold change relative to an average level of the 4 w.o.
BALB/c mice (mean 6 SEM, n=5), after normalization for the expression level
of a house-keeping gene in the same sample (Mouse ACTB (actin, beta)
Endogenous Control (4352933E) and TATA-box binding protein
(Mm00446973_m1).
bendonuclease G.
cDNA fragmentation factor, alpha subunit.
dDNA fragmentation factor, beta subunit.
ecell death-inducing DNA fragmentation factor, alpha subunit-like effector B.
fsignificantly reduced Dnase1 gene expression only in kidneys from proteinuric
B/W mice.
gReal time PCR was performed on ABI Prism 7900HT Sequence Detection
System with the TaqMan Gene Expression Assay indicated for each gene.
doi:10.1371/journal.pone.0012096.t001
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PLoS ONE | www.plosone.org 2 August 2010 | Volume 5 | Issue 8 | e12096Figure 1. Total nuclease activity, Dnase1 and Dnase1l1-3 expression in kidneys from BALB/c and (NZBxNZW)F1 mice. Pre-proteinuric
and proteinuric B/W kidneys were used, the latter divided into 2 groups; one characterized by immune complex deposits in glomerular mesangial
matrix only (labeled ‘‘Mesangial deposits’’), and the other with immune complex deposits in both the mesangial matrix and the capillary membranes
(labeled ‘‘Capillary deposits’’). (A) Kidney lysates (black) or sera (grey), in which total protein was measured, and protein content of the samples
normalized using BCA assay (Pierce), were applied onto 1% agarose gels containing calf thymus DNA and ethidium bromide in a CaCl2- and MgCl2-
containing buffer, pH 7.6, and incubated in a humidified chamber at 37uC for 24 hours. The gel was photographed under UV illumination. The radius
of the non-fluorescent area surrounding each well reflected DNase activity in the sample. DNase activity is expressed as Dnase1 equivalent units, by
comparison with human recombinant Dnase1. (B) Total nuclease activity in renal homogenates is shown for native samples, after addition of 5mg/mL
monomeric actin and after preheating the samples to 50uC for 10 minutes prior to incubation on the gel, reflecting the results of addition and
reversal of actin inhibition, respectively. The group labeled ‘‘young’’ represent 10 and 20 week old B/W, whereas the ‘‘Mesangial’’ and ‘‘Capillary’’
groups reflect proteinuric B/W with immune complex deposits in the mesangium and GBM, respectively. DNase activity is expressed as Dnase1
equivalent units, by comparison with human recombinant Dnase1. In panels C and D the order of samples are kidneys from normal age matched
BALB/c (lanes 1–3), pre-nephritic B/W kidneys (lanes 4–6), nephritic B/W kidneys with mesangial matrix deposits only (lanes 7–9), and nephritic B/W
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SRED activity in mice of all age groups, with similar residual
Dnase activity in proteinuric and non-proteinuric mice (Figure 1B).
These data suggest that the observed reduction in serum and renal
Dnase activity is caused by the loss of one or more actin-
inhibitable factors. Preheating the samples to 56uC for 10 minutes,
previously reported to reverse Dnase1 inhibition by actin [22,35],
caused a proportionally similar increase in SRED activity in both
serum and renal homogenates in mice of all ages (Figure 1B),
suggesting that inhibition of Dnase1 by actin does not explain the
observed differences in nuclease activity in these mice. Inhibition
of the actin-resistant Dnase1 homologue Dnase1l3 using the
selective inhibitor DR396 showed no differences in Dnase activity
by the SRED assay in any mice (data not shown). Gel zymography
of sera showed enzyme activity confined to a single band
corresponding in size to Dnase1, which was completely inhibited
by incubating the gel in the presence of actin (data not shown).
While serum nuclease activity was reduced in mesangial and
membranoproliferative nephritis, renal Dnase1 activity was
reduced only in membranoproliferative nephritis. These results
suggest that changes in renal nuclease activity are due to changes
intrinsic to the kidney, and not a passive reflection of serum DNase
activity. The fact that there is a parallel loss of renal Dnase1
mRNA and the Dnase1 protein (Figure 1C), argue that the loss of
Dnase1 in the kidney is a consequence of shut-down of gene
expression.
Dnase1 expression and zymography
To evaluate how reduced renal Dnase1 gene expression affects
enzymatic activity in the proteinuric mice, Dnase1 activity in
kidney homogenates was assayed after electrophoretic separation
of proteins in DNA-containing gels. Renal Dnase1 mRNA
expression levels in the individual samples were compared with
zymographic renal Dnase1 activity in the same mice (Figure 1C
and D for gene expression and zymography, respectively).
Zymography revealed DNA-degrading activity predominantly in
a band corresponding to the molecular weight of recombinant
human Dnase1 (Figure 1D, lanes 1–3 for BALB/c, lanes 4–6 for
pre-nephritic B/W mice, and lanes 7–12 for nephritic B/W mice).
Activity in this band was completely eliminated in all samples
when incubation of the gel was performed in the presence of actin
(data not shown), further identifying the responsible enzyme as
Dnase1. The samples obtained from nephritic B/W mice clearly
separated into two distinct groups: those with mild nephritis and
immune complex deposits confined to the mesangial matrix
demonstrated normal levels of Dnase1 mRNA and Dnase1
enzyme activity (Figure 1C and D, lanes 7–9), whereas mice with
severe nephritis and IC deposits within the capillary membrane
showed dramatically reduced Dnase1 mRNA and enzyme activity
(Figure 1C and D, lanes 10–12). Thus, there was a consistent
correspondence between levels of Dnase1 mRNA expression and
Dnase1 activities within the same kidneys. Several weak bands of
high molecular weight (100–150kDa) with DNA-degrading
activity were also observed, with similar intensity in all samples
from both pre-nephritic and nephritic kidneys (data not shown).
Renal mRNA expression of the Dnase1 homologues Dnase1-
like 1, -2, -3 was also assayed in the various groups of mice. The
results demonstrated no evidence of significant nephritic stage
reduction or compensatory up-regulation of any of these nucleases
(Figure 1E, p=0.1768 for Dnase1l1, p=0.1497 for Dnase1l2,
p=0.0780 for Dnase1l3). A tendency for gradual elevation of
Dnase1l3 expression with nephritis progression was observed,
however, no formal statistical significance was reached when either
parametric (ANOVA) or non-parametric (Kruskal-Wallis) tests
were applied.
Detection of renal Dnase1 protein by western blotting
In order to clarify whether the low Dnase1 activity in the kidney
homogenates from B/W mice with membranoproliferative
nephritis was due to inhibition of enzyme activity or to an
absolute reduction in renal Dnase1 protein amount, western
blotting was performed on the same samples that were used for
SDS-PAGE gel zymography (Figure 1D). A single band was seen,
corresponding to the MW of recombinant human Dnase1
(rhDnase1, approximately 32 kDa, Figure 1D). Very low band
intensities were found in the kidney samples that demonstrated
considerably reduced Dnase1 mRNA levels and Dnase1 enzyme
activity (Figure 1D, lanes 10–12), whereas mice with normal
mRNA expression and mesangial matrix deposits only, had
Dnase1 protein expression comparable to the normal control and
pre-proteinuric mice (Figure 1D, lanes 7–9). Immunoblotting to
detect actin in the same samples demonstrated that the low
Dnase1 band intensity in lanes 10–12 could not be explained
by unequal loading of the samples on the gel. (Figure 1D).
Immunoblotting against Dnase1l1 showed similar levels of expres-
sion in kidneys from B/W mice of all ages (data not shown).
In situ DNA-degradation assay
To visualize areas of renal nuclease activity in situ, non-fixed
cryosections of kidneys were incubated in DNase reaction buffer to
allow enzymatic cleavage of endogenous nuclear DNA by
nucleases present in the tissue. The DNA nicks generated by
endogenous nucleases were identified by terminal deoxynucleoti-
dyl transferase-mediated incorporation of dUTPs labeled with a
fluorescent marker. The signals generated were present in nuclei of
renal cells in BALB/c (Figure 2A and B) and in pre-nephritic B/W
(Figure 2C and D) mice, while significantly reduced intensity was
observed in proteinuric B/W mice with capillary membrane
chromatin-IgG deposits (Figure 2E and F). The reaction was
completely blocked by EDTA (Figure 2B, insert labeled B’),
confirming that the DNA degradation was divalent cation-
dependent, and no signal was seen upon immediate fixation with
paraformaldehyde (data not shown). These results corresponded
well with data presented in Figure 1.
Detection of the renal Dnase1 protein in situ by indirect
immunofluorescence in murine and human forms of
lupus nephritis
Tissue localization of Dnase1 and its possible contribution to the
in situ DNA-fragmentation ability as presented in Figure 2, was
analyzed by indirect immunofluorescence. For a better overview of
morphology of the sections, matched phase contrasts and im-
munofluorescence micrographs have been included (Figure S2).
Staining of normal BALB/c kidneys with an anti-Dnase1 antibody
kidneys with capillary membrane deposits (lanes 10–12). All kidney samples were analyzed for fold change of renal Dnase1 mRNA levels relative to 4
weeks old BALB/c mice (C), zymography of Dnase1 activity in 10% SDS-polyacrylamide gel of kidney lysates (D, upper part), and western blot of
Dnase1 in the same samples (D, lower part). Western blotting to detect actin in the same samples demonstrated that the low Dnase1 band intensity
in lanes 10–12 was not due to unequal loading of the samples on the gel. Renal mRNA expression of Dnase1l1 (TaqMan assay Mm00510102_m1),
Dnase1l2 (Mm00481868_g1) and Dnase1l3 (Mm00432865_m1) was not decreased in kidneys from proteinuric mice (E).
doi:10.1371/journal.pone.0012096.g001
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kidney, with weaker staining within glomeruli. Similar staining was
observed in B/W mice with mesangial chromatin-IgG deposits
(Figure 3B). Proteinuric mice with deposits in capillary membranes
had significantly reduced staining of immunoreactive Dnase1 in
both tubuli and glomeruli (Figure 3C, see also Figure S2 for
details) compared to healthy BALB/c controls and younger pre-
diseased B/W mice. Immunofluorescence staining of Dnase1l1
showed low levels of staining with comparable intensity in kidneys
from mice of all ages (data not shown).
To analyze if the down-regulation of Dnase1 gene expression
and corresponding Dnase1 enzyme activity observed in nephritic
BW mice was also relevant in human lupus nephritis, Dnase1
immunostaining was performed on histologically normal human
kidney biopsies (Figure 3D) and to biopsies from patients with mild
(Patient A, Figure 3E) and membranoproliferative (Patient B,
Figure 3F) lupus nephritis. The data revealed a dramatic decrease
in Dnase1 immunostaining only in renal sections from the patient
with severe nephritis. For a better overview of morphology of
the sections, matched phase contrast and immunofluorescence
micrographs have been included for biopsies from patients A and
B, respectively (Figure S3A–B). This figure demonstrates that the
Dnase1 protein is lost both in tubular and glomerular cells in the
latter kidney biopsy (Figure S3B). Crithidia luciliae immunofluores-
cence titer (CLIFT) and serum creatinine levels for Patients A and
B are shown in Figure 3G. Immune electron microscopy, where in
situ bound IgG was detected by rabbit anti-human IgG antibody
followed by binding of gold-labeled protein A [36], showed
chromatin-IgG deposits predominantly in the mesangial matrix of
Patient A (Figures 3H–I), while in the biopsy from Patient B, the
deposits were widely distributed in both glomerular basement
membranes (GBM) and the mesangial matrix (Figure 3J). These
data parallel the association between reduced renal Dnase1
expression and the occurrence of membranoproliferative lupus
nephritis seen in B/W mice. Results from Dnase1 staining of
additional biopsies from patients with lupus nephritis revealed a
similar relationship between Dnase1 staining intensity and the
glomerular loci for chromatin-IgG complex deposits (Figure S4).
Moreover, Dnase1 staining in a biopsy of a Wegener’s granu-
lomatosis patient with severe pauci-immune glomerulonephritis
was comparable to that of normal kidneys (Figure S4D), suggesting
that the observed reduction in Dnase1 staining is specific for lupus
nephritis, and not a general element of particular patterns of
nephritis.
Discussion
Dnase1 has been implicated in SLE pathogenesis through a
number of studies in both mice and humans [23,25,37]. The
kidney is one of the major loci for Dnase1 production and activity.
Other organs with Dnase1 expression include salivary glands, liver
and gastrointestinal tract cells [38]. In humans but not rodents, the
pancreas appears to be an important source of Dnase1 [39]. The
relative contribution of each of these organs to the circulating pool
of Dnase1 in blood and urine remains uncertain. Dnase1 is the
principal renal nuclease, reported to account for more than
80% of the total endonuclease activity within the kidney [40].
Interestingly, decreased levels of urine nuclease activity has been
found in lupus-prone B/W mice, preceding the development of
renal disease manifestation [25]. Since it has been shown that
Figure 2. Low rate of nucleolysis in proteinuric (NZBxNZW)F1 kidneys. Non-fixed cryosections of kidneys were incubated in DNase reaction
buffer (2mM CaCl2, 2mM MgCl2 in 40mM Tris, pH7.6) to allow enzymatic cleavage of endogenous DNA by nucleases present in the tissue. TUNEL-
based detection of DNA fragmentation was performed after 2h incubation at 37uC. Results are given as TUNEL-stained endogenous DNA in kidney
sections from 20 w.o. (A) and 32 w.o. (B) BALB/c, 8 w.o. (C), 20 w.o. (D) and proteinuric 28 w.o. (E) and proteinuric 34 w.o. (F) B/W mice. The 2 latter
mice suffered from membranoproliferative nephritis with very low renal Dnase1 mRNA levels and Dnase1 enzyme activity. Control analyses were
performed by adding 20 mM EDTA to the reaction buffer. This completely abolished TUNEL staining in 34 w.o. BALB/c kidneys (see inserted panel B’
in panel B) as well as in kidneys from young and proteinuric B/W mice (data not shown). Similarly, immediate fixation of the tissue sections with
paraformaldehyde also resulted in absence of nicked DNA (data not shown).
doi:10.1371/journal.pone.0012096.g002
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renal shut-down of the enzyme could be relevant to explain
development of lupus nephritis, including deposition of large
chromatin fragments (reviewed in [3,42]).
Using both morphological and zymographic methods, the
current work extends previous data demonstrating an acquired,
selective down-regulation of renal Dnase1 gene expression linked to
progression towards end-stage lupus nephritis. The existence of
several Dnase1-like enzymes with similar biochemical properties
makes it important to assay Dnase activity by several methods to
verify the identity of the responsible nucleases. Inhibition by actin
is only seen for Dnase1 [43] and possibly Dnase1l1 [44]. Quan-
titative mRNA and immunofluorescence assays demonstrated no
evidence of decreased levels of Dnase1l1 in the kidneys of
proteinuric mice. We demonstrate here i. that the level of renal
Dnase1 mRNA expression is reflected by enzyme activity
and Dnase1 protein expression, ii. the relative contribution of
renal Dnase1 to total renal nuclease activity, iii. the renal location
of Dnase1 protein expression and loss of Dnase1 protein
expression during progression of lupus nephritis, and finally iv.
the relevance of decreased renal Dnase1 for progression of human
lupus nephritis. The discrepancy between serum and renal
nuclease activity within the proteinuric group, as well as the
consistency of assays of mRNA, protein and enzymatic activity
levels, strongly favors reduced renal Dnase1 synthesis as the major
contributor to reduced renal Dnase1 activity.
Figure 3. Expression of immunoreactive Dnase1 in kidneys from (NZBxNZW)F1 mice and from patients with lupus nephritis.
Cryosections of B/W and human kidneys were immunostained with rabbit anti-Dnase1 antibody followed by an Alexa488-conjugated F(ab’)2 anti-
rabbit IgG antibody. The images were taken using identical exposure settings. The images were obtained at 4006magnification on kidney sections
from a 32 w.o. BALB/c mouse (A), a 20 w.o. B/W mouse with mesangial nephritis (B) and a 32 w.o. nephritic B/W mouse with membranoproliferative
nephritis and low renal Dnase1 activity (C). In the kidneys of the latter mouse, only traces of the Dnase1 enzyme could be detected. Similarly, there
was robust Dnase1 staining in a kidney biopsy from a histologically normal kidney (D), a patient with mesangial nephritis (Patient A, panels E, H and I
), whereas only traces of Dnase1 staining was detectable in kidneys from a patient with membranoproliferative lupus nephritis (Patient B, panels F
and J). Crithidia luciliae immunofluorescence titers (CLIFT) and serum creatinine levels of the two patients are shown (panel G). Immune electron
microscopy using protein-A-gold conjugated rabbit anti-human IgG antibodies revealed predominantly mesangial electron-dense structures (EDS) in
patient A with mild nephritis (panels H-I), whereas glomerular as well as mesangial EDS were present patient B with severe nephritis (panel J).
doi:10.1371/journal.pone.0012096.g003
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glomerular IC deposits observed as electron dense structures
(EDS) by transmission electron microscopy [45,46,47,48]. In a
recent report, we correlated patterns of immune complex deposits
with renal mRNA expression of Dnase1 [32]. Whereas mesangial
EDS were detectable in all mice that produced anti-dsDNA
antibodies, a clear correlation was seen between reduced renal
Dnase1 expression and the formation of capillary sub-endothelial
and sub-epithelial deposits, and the development of membrano-
proliferative nephritis. Our current data confirms that these
associations are indeed reflected in a kidney-specific decrease in
renal Dnase1 activity. This change may represent an important
factor in the progression of mesangial lupus nephritis into end-
stage renal disease.
The results of the present immunofluorescence studies on renal
biopsies from SLE patients suggest that changes in Dnase1
expression similar to those seen in the B/W mice are relevant to
explain disease progression also in humans. Previous data have
demonstrated a constitutive defect causing reduced oligonucleo-
somal DNA fragmentation in kidneys of B/W mice of all ages
upon induction of apoptosis in kidneys of B/W mice using the
topoisomerase I inhibitor camptothecin [34]. These results
therefore led us to investigate whether such a defect could be
explained by constitutively reduced expression of one or more of
the nucleases responsible for apoptotic DNA fragmentation. In the
present report we did not find evidence of decreased total nuclease
activity in young B/W mice. This would suggest that the basis of
such a camptothecin-related defect lies upstream in the apoptotic
signaling cascade. Although not related to the reported reduction
in apoptotic DNA fragmentation, there is a striking association
between the fall in renal Dnase1 enzyme activity and the
accumulation of chromatin fragment-containing IC within the
GBM. Because Dnase1 is the major endonuclease within the
kidney ([40], present results), an uncompensated reduction in renal
Dnase1 activity could contribute to a reduced clearance and
secondary exposure of chromatin debris within the kidney.
Exposed secondary necrotic chromatin triggers pro-inflammatory
signaling in phagocytes, and constitutes an important danger
signal [49]. Failure of phagocytic clearance of apoptotic and/or
necrotic cells has been postulated as a possible driving force for
sustained anti-chromatin autoimmunity [42,46,50,51]. If apoptotic
chromatin is exposed, e.g. as a result of diminished renal Dnase1
activity, this could trigger renal inflammation and leukocyte
infiltration, and at the same time provide a target for circulating
anti-chromatin antibodies. In the face of pre-existing, florid
autoreactivity, such changes could conceivably launch a rapidly
progressive organ-centered immune attack, causing proteinuria
and renal failure.
The fact that down-regulation of Dnase1 in the kidneys appears
after initiation of anti-dsDNA antibody production indicates that
loss of renal nuclease activity is not responsible for the appearance
of anti-chromatin autoimmunity. Moreover, Wilber et al. have
identified a mutation in the Dnase1l3 gene in the B/W mice that
reduced the ability of this enzyme to fragment DNA [52]. This
nuclease has been proposed to play a role during apoptotic
chromatin degradation [53,54]. Whether this defect has any
impact on development of anti-chromatin antibodies and lupus
nephritis has not been determined. Considering such data, and the
data presented in this study, several defects in the apoptotic
processing and elimination of DNA may together contribute to
initiation and progression of e.g. lupus nephritis in these animals.
However, inhibition of Dnase1l3 using a specific inhibitor did not
significantly alter serum or renal Dnase activity in B/W or BALB/
c mice of any ages, suggesting a modest contribution of this
endonuclease to total nuclease activity in the circulation and
within the kidneys.
Existing data are conflicting on the issue of whether a reduced
total serum nuclease activity is present in pre-nephritic B/W mice
[25,52]. In the present study, no reduction in activity was found in
pre-proteinuric mice. Still, the consistent decrease seen in serum
nuclease activity in all proteinuric mice irrespective of the levels of
renal total nuclease expression indicate that similar changes could
occur in other organs, including the liver. Such changes might
therefore be of relevance to the loss of immunological tolerance
against DNA and nucleosomes, and is currently being analyzed in
our laboratory. Furthermore, the lack of a consistent correlation
between serum and renal Dnase1 activity suggests that these reflect
separate processes; the latter possibly confined to the kidney and
related to the development of particularly unfavorable patterns of
progression of the renal disease.
Considering the widespread hypothesis that SLE is related to
deficient clearance of apoptotic debris, and in particular to the
removal of chromatin-associated antigens, impaired production of
a key secreted renal nuclease in a spontaneous model of the disease
is a striking observation. An acquired down-regulation of Dnase1
expression during the development of lupus nephritis could be
relevant to understand how systemic autoimmunity translates into
end-organ disease, and could prove useful as a clinical marker for
renal disease in SLE, as discussed by Mortensen et al. [42].
Identifying the processes underlying the observed down-regulation
of renal Dnase1 is a complex feat, and is the focus of ongoing
investigations.
Materials and Methods
Ethics Statement
The National Animal Research Authority (NARA) approved
the study. Treatment and care of animals were conducted in
accordance with guidelines of the Norwegian Ethical and Welfare
Board for Animal Research. The study was approved by the
Regional Ethical Committees in Lund, Sweden, and in Northern
Norway.
Collection of samples from B/W and BALB/c mice
Female B/W and BALB/c mice were purchased from Harlan
(Blackthorn, UK). Serum samples were collected every second
week. Proteinuria was monitored weekly with sticks from Bayer
Diagnostics (Bridgend, UK). Staining of $3+ ($3 g/L) was
regarded as proteinuria indicative of overt nephritis. Kidneys were
extirpated from B/W mice of different ages and from gender- and
age-matched BALB/c control mice (Table 1), cut and snap-frozen
in liquid N2 with or without OCT (Optimal Cutting Temperature,
Tissue-Tek, Terrance, CA), fixed in buffered depolymerised
paraformaldehyde for electron microscopy studies, or stored in
RNAlater (Ambion Inc, Austin, TX) for studies of gene expression.
Treatment and care of animals were conducted in accordance
with guidelines of the Norwegian Ethical and Welfare Board for
Animal Research, and the institutional review board approved the
study.
Human kidney biopsies
Kidney biopsies from female SLE patients with nephritis, and
from patients with renal cancer or from a patient with Wegener’s
granulomatosis, were collected, prepared, and stored as described
previously [45]. Baseline data for the SLE patients are presented in
Figure 3. The glomeruli from the Wegener kidney were devoid of
glomerular chromatin-IgG deposits, and the patient did not
produce anti-dsDNA antibodies [55].
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Serum anti-DNA autoantibodies were detected by ELISA as
previously described [34,36,56].
Renal mRNA levels of nuclease-encoding genes
RNA extraction, cDNA synthesis and real time PCR were
performed as previously described [34]. All reagents and assays
were from Applied Biosystems. The primers and probes used are
presented in Table 1 and in legend to Figure 1 for Dnase1l1/2/3.
Expression levels relative to those of 4 w.o. BALB/c mice were
calculated for all groups using the ddCT method.
Protein extraction
Nuclear and nucleus-depleted lysates were prepared from 20mg
pieces of snap-frozen, lyophilized kidney tissue using Pierce
Nuclear and Cytoplasmic Extraction reagent kit (Pierce Biotech-
nology, Rockford, IL,). Total protein was measured, and protein
content of the samples normalized using BCA assay (Pierce).
Radial nuclease diffusion assay
To evaluate nuclease activity within native protein samples, a
nuclease radial diffusion assay was performed as described [57],
with minor modifications. Briefly, 1ml aliquots of renal lysates or
serum samples were loaded in 1mm Ø wells on a 1% agarose gel
containing 150 mg/ml calf thymus DNA (Sigma-Aldrich GmbH,
Steinheim, Germany) and 1 mg/ml ethidium bromide in DNase
reaction buffer (40 mM Tris, pH 7.6, 2 mM CaCl2 and 2 mM
MgCl2). The gel was incubated in a humidified chamber at 37uC
for 19 hours and photographed under UV illumination.
Heat inactivation of actin was achieved by incubation of
samples in a heating block at 56uC for 10 minutes. Dnase1l3
inhibition was performed by addition of 4-(4,6-dichloro-[1,3,5]-
triazin-2-ylamino)-2-(6-hydroxy-3-oxo-3H-xanthen-9-yl)-benzoic
acid (DR396; Sigma-Aldrich) to a concentration of 5mM. Actin
inhibition was achieved by pre-incubating the samples with 5mg/
mL bovine g-actin (Sigma-Aldrich) for 10 minutes.
DNase zymography
DNA degrading activity by Dnase1 was determined after
protein separation in a 10% SDS-polyacrylamide gel containing
100mg/ml heat-denatured salmon sperm DNA (Invitrogen Corp.,
Carlsbad, CA) as described [58]. For actin inhibition experiments,
the gels were incubated for 4 hours at RT in 40mM Tris pH 7.4
containing g-actin at a concentration of 5m g/mL, and 5mg/mL
actin was also added to the Dnase reaction buffer, adapting a
previously published protocol [27].
Western blotting
The renal protein extracts (25mg/lane) were separated using
10% SDS-PAGE gels, transferred onto PVDF membranes, and
incubated with goat anti-mouse Dnase1 antibodies or goat anti-
human Dnase1l1 antibodies (Santa Cruz Biotechnology, Santa
Cruz, CA, USA). Binding was visualized using SuperSignal
Chemiluminescent Substrate (Pierce) after incubation with HRP-
conjugated anti-goat IgG. Equal loading was confirmed by
membrane stripping and reprobing with a rabbit anti-human
actin IgG (Sigma-Aldrich).
In situ DNA degradation assay
Four mm thick sections of OCT-embedded kidneys were
incubated in DNase reaction buffer (2mM CaCl2, 2mM MgCl2
in 40mM Tris, pH7.6) for 2h at 37uC. The sections were then
fixed with 4% paraformaldehyde and assayed using a fluorescent
terminal deoxynucleotidyl transferase dUTP nick end label-
ing (TUNEL) assay kit (Roche Applied Science, Mannheim,
Germany).
Direct immunofluorescence microscopy
Four mm thick cryosections from murine and human kidneys
were blocked for 1h with 10% goat serum and 1% bovine serum
albumin (BSA) in phosphate-buffered saline (PBS) followed by
30 min incubation with Alexa Fluor 488-conjugated F(ab’)2 goat
anti-mouse or anti-human IgG (Invitrogen) and overnight washing
in 0.05% Tween-20 in PBS at +4uC.
Transmission electron microscopy (TEM) and co-
localization immune electron microscopy (IEM)
TEM and co-localization IEM of murine kidney sections were
performed exactly as described by Kalaaji et al. [36,46].
Indirect immunofluorescence staining
Four mm sections from mouse kidneys embedded in OCT were
blocked for 1 hour with 10% goat serum and 1% BSA in PBS
followed by washing with PBS and 30 min incubation with goat
anti-mouse Dnase1 or anti-human Dnase1l1 antibody (Santa Cruz
Biotechnology) or normal goat IgG (negative control). Slides
were washed and incubated for 30 min with Alexa Fluor 488-
conjugated F(ab’)2 anti-goat IgG (Invitrogen). Kidney sections
from the same mice were incubated with a buffer containing 10%
goat serum, 10% fetal calf serum or with 5% BSA in PBS prior to
staining with anti-Dnase1 antibody. No difference in Dnase1
staining intensity was seen between these samples. For the human
cryopreserved biopsies, rabbit anti-bovine/human Dnase1 anti-
body (US Biological, Swampscott, Massachusetts) and Alexa Fluor
488-conjugated F(ab’)2 anti-rabbit IgG (Invitrogen) were used as
first and second antibody, respectively.
Statistics
Statistics were performed with GraphPad Prism 5 (GraphPad
Software, San Diego, CA) using the Mann-Whitney U test for
comparison of groups. Differences were considered statistically
significant at p,0.05.
Supporting Information
Figure S1 Electron microscopy examination of immune com-
plex deposition in proteinuric (NZBxNZW)F1 mice. Kidney
morphology was further studied on ultrathin kidney sections by
transmission electron microscopy (A, C, E) to define loci for
deposition of electron dense structures, and by co-localization IEM
(B, D, F) to detect in vivo-bound IgG (traced by 5nm gold), and
chromatin deposits (traced by a monoclonal anti-dsDNA antibody
added in vitro to the sections and stained by 10nm gold). In a 28
w.o. B/W mouse with mild proteinuria and sub-normal level of
renal Dnase1 activity, the bound anti-dsDNA mAb co-localized
with autoantibodies in EDS in the mesangial matrix (Fig. 4A and
4B demonstrate mesangial matrix-associated EDS by TEM, while
the anti-dsDNA mAb added to the section in vitro co-localized
with in vivo-bound IgG strictly confined to EDS as demonstrated
by co-localization IEM, respectively). In a 35 w.o. proteinuric (+3)
B/W mouse with low renal Dnase1 activity, the immune complex
deposits were observed as EDS in glomerular capillary walls and
mesangial matrix by TEM (C). Co-localization IEM demonstrated
that these EDS contained IgG molecules and targets for the anti-
dsDNA mAb (D). In a 20 w.o. pre-nephritic B/W mouse, TEM (E)
revealed normal glomeruli, while co-localization IEM (F) revealed
circulating chromatin-containing immune complexes within
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complexes were associated with membranes or the mesangial
matrix. BALB/c mice had normal kidney morphology and no
immune complexes were detected by TEM or co-localization IEM
(data not shown). In D, it is demonstrated that the anti-dsDNA
mAb, added to the sections and traced by 10 nm gold, bound to
nuclear DNA.
Found at: doi:10.1371/journal.pone.0012096.s001 (3.00 MB TIF)
Figure S2 Phase contrast and indirect immunofluorescence
analyses of Dnase1 staining on pre-nephritic and nephritic
(NZBxNZW)F1 kidneys. Cryosections of B/W kidneys were
analysed by phase-contrast and indirect immunofluorescence
using an anti-Dnase1 antibody followed by an Alexa488-
conjugated F(ab’)2 anti-IgG antibody to stain for Dnase1. The
images were taken using identical exposure settings, and were
obtained at 2006magnification. Phase-contrast micrographs and
corresponding Dnase1 stainings are shown for a pre-nephritic
B/W mouse (20 weeks old; panel A), a mouse with mesangial
nephritis (panel B) and a mouse with membrano-proliferative
nephritis (panel C). Glomeruli have been marked by circles for
clarity. As is evident from the figure, Dnase1 is expressed in
tubular and glomerular cells, and both compartments loose their
Dnase1 expression upon progression of lupus nephritis into end-
stage organ disease.
Found at: doi:10.1371/journal.pone.0012096.s002 (3.00 MB TIF)
Figure S3 Phase contrast and indirect immunofluorescence
analyses of Dnase1 staining of kidney biopsies from patients with
lupus nephritis. Cryosections of the kidneys were analysed by
phase contrast and indirect immunofluorescence using an anti-
Dnase1 antibody followed by an Alexa488-conjugated F(ab’)2
anti-IgG antibody to stain for Dnase1. The images were taken
using identical exposure settings at 2006 magnification. Corre-
sponding phase-contrast micrographs and Dnase1 immunostain-
ings are shown for a patient with mild mesangial (A) and
membrano-proliferative (B) lupus nephritis. Glomeruli have been
marked by circles for clarity.
Found at: doi:10.1371/journal.pone.0012096.s003 (3.00 MB TIF)
Figure S4 Indirect immunofluorescence analyses of histological-
ly normal kidneys and biopsies from patients with Wegener
granulomatosus and lupus nephritis. The renal cryosections were
immunostained with rabbit anti-Dnase1 antibody followed by an
Alexa488-conjugated F(ab’)2 anti-IgG antibody. The images were
obtained at 4006magnification using identical exposure settings.
Strong staining was visible in histologically normal kidneys (A–C).
Comparable levels of staining were present in kidneys from a
patient with Wegeners granulomatosis (D) and from mesangial
lupus nephritis (E), whereas Dnase1 staining was almost
undetectable in kidneys from patients with membrano-prolifera-
tive lupus nephritis (F–H).
Found at: doi:10.1371/journal.pone.0012096.s004 (3.00 MB TIF)
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